GTX Inc. (GTXI) Friday revealed a reduction in force reflecting the delay in the potential commercialization of toremifene 80 mg to reduce fractures in men with prostate cancer on androgen deprivation therapy. The reduction in force, effective immediately, represents approximately 28% of the total workforce. The company also said that the employees remaining with the company would not receive an increase in base salaries for 2010 or any bonus compensation for 2009.
GTx expects to record a charge of approximately $1.1 million related to the workforce reduction in the fourth quarter of 2009.
For comments and feedback: editorial@rttnews.com